摘要
目的观察和比较培美曲塞联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床治疗效果及不良反应发生情况.方法选取2013年6月至2015年6月期间昆明医科大学第三附属医院收治的42例晚期非小细胞肺癌患者,按随机数字法平均分为观察组与对照组,每组各21例.观察组采用培美曲塞联合顺铂治疗,对照组采用紫杉醇联合顺铂治疗.观察2组患者治疗2个疗程后(21 d/疗程)的临床治疗效果以及不良反应的发生情况并对其进行统计分析比较.结果观察组和对照组治疗有效率(RR)分别为33.33%(7/21)和28.57%(6/21);临床受益率(CBR)分别为76.19%(16/21)和71.43%(15/21);2组RR和CBR比较差异无统计学意义(P>0.05).观察组的毛发脱落发生率23.81%(5/21)、不良反应合计数比例18.37%(27/147)显著低于对照组47.62%(10/21)、25.17%(37/147)(P<0.05).在白细胞下降、中性粒细胞下降、红细胞下降、血小板下降、恶心呕吐、静脉炎的不良反应发生率比较,2组差异无统计学意义(P>0.05).结论培美曲塞联合顺铂治疗晚期非小细胞肺癌与紫杉醇联合顺铂的临床治疗效果相接近,但培美曲塞联合顺铂治疗的不良反应相对较少、安全性相对较高,在临床治疗中更具有推广应用的价值.
Objective To observe the clinical efficacy and adverse reactions between pemetrexed plus cisplatin and paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods Forty-two cases with non-small cell lung cancer in our hospital from June 2013 to June 2015 were selected. Patients were randomly divided into observation group and control group with 21 cases in each group. The observation group was treated with pemetrexed plus cisplatin and the control group was treated with paclitaxel plus cisplatin. The clinical efficacy and adverse reactions were observed after two courses（21 days of a course） and the statistical analysis was performed. Results In the observation group and control group, response rate and clinical benefit rate were 33.33%（7/21）,28.57%（6/21） and 76.19%（16/21）, 71.43%（15/21） respectively. No statistical significance were seen between the two groups（P〈0.05）.The rate of hair loss（23.81%）（5/21） and the total number of adverse reactions（18.37%）（27/147） in the observation group were significantly lower than the rate of hair loss（47.62%）（10/21） and the total number of adverse reactions（25.17%）（37/147） in the controlgroup（P〈0.05）. No statistical significance was found in the incidence rate of leukopenia, neutropenia,erythropenia, thrombocytopenia, nausea and vomiting and phlebitis between the two groups（P〈0.05）.Conclusion Pemetrexed plus cisplatin is as effective as paclitaxel plus cisplatin in the treatment of advanced NSCLC with less adverse reactions and is much safer than paclitaxel plus cisplatin. Pemetrexed plus cisplatin is more valuable in the clinical treatment of advanced NSCLC.
作者
陈楠
张莹
李恒
郭刚
向旭东
马千里
李高峰
CHENNan ZHANGYing LIHeng GUOGang XIANGXu-dong MAQian--li LIGAO-feng(Third Affiliated Hospital of Kunming Medical University, Department of Thoracic Surgery, Kunming Yunnan 650118, China)
出处
《昆明医科大学学报》
CAS
2016年第9期96-99,共4页
Journal of Kunming Medical University
基金
云南省应用基础研究基金资助项目(2010CD185)
云南省社会发展科技计划基金资助项目(2010CA015)
关键词
培美曲塞
紫杉醇
顺铂
晚期非小细胞肺癌
临床疗效
Pemetrexed
Paclitaxel
Cisplatin
Advanced non-small cell lung cancer
Clinical efficacy
